EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis

Verfasser / Beitragende:
[Daniela Proença, Clara Leandro, Miguel Garcia, Madalena Pimentel, Carlos São-José]
Ort, Verlag, Jahr:
2015
Enthalten in:
Applied Microbiology and Biotechnology, 99/12(2015-06-01), 5137-5149
Format:
Artikel (online)
ID: 60550069X
LEADER caa a22 4500
001 60550069X
003 CHVBK
005 20210128100557.0
007 cr unu---uuuuu
008 210128e20150601xx s 000 0 eng
024 7 0 |a 10.1007/s00253-015-6483-7  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00253-015-6483-7 
245 0 0 |a EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis  |h [Elektronische Daten]  |c [Daniela Proença, Clara Leandro, Miguel Garcia, Madalena Pimentel, Carlos São-José] 
520 3 |a Bacteriophage lytic enzymes, either endolysins or virion-associated lysins, have been receiving considerable attention as potential antibacterial agents, particularly for the combat of antibiotic-resistant Gram-positive pathogens. A conclusion that easily emerges from the careful analysis of a great number of reports on the field is that the activity of phage lytic enzymes is rarely studied in conditions that support robust growth of the target bacteria. Here, we report the construction and study of a chimerical lysin, EC300, which was designed to target and kill Enterococcus faecalis in conditions supporting vigorous bacterial growth. EC300 resulted from the fusion of a predicted M23 endopeptidase domain of a virion-associated lysin to the putative cell wall binding domain of a previously characterized amidase endolysin, both produced by the E. faecalis phage F170/08. This bacteriolysin-like protein exhibited a clear enhanced lytic activity over the parental endolysin when both were assayed in a rich bacterial growth medium. We demonstrate the killing efficacy of EC300 against growing cells of a panel of typed E. faecalis clinical strains with high level of antibiotic resistance. The possible reasons for the marked difference between the lytic performance of EC300 and that of the amidase are discussed. 
540 |a Springer-Verlag Berlin Heidelberg, 2015 
690 7 |a Virion-associated lysin  |2 nationallicence 
690 7 |a Endolysin  |2 nationallicence 
690 7 |a Chimerical enzyme  |2 nationallicence 
690 7 |a Peptidoglycan hydrolase  |2 nationallicence 
690 7 |a Enterococcus faecalis  |2 nationallicence 
700 1 |a Proença  |D Daniela  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
700 1 |a Leandro  |D Clara  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
700 1 |a Garcia  |D Miguel  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
700 1 |a Pimentel  |D Madalena  |u Centro de Patogénese Molecular, Unidade dos Retrovírus e Infecções Associadas (CPM-URIA), Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal  |4 aut 
700 1 |a São-José  |D Carlos  |u Centro de Patogénese Molecular, Unidade dos Retrovírus e Infecções Associadas (CPM-URIA), Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal  |4 aut 
773 0 |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/12(2015-06-01), 5137-5149  |x 0175-7598  |q 99:12<5137  |1 2015  |2 99  |o 253 
856 4 0 |u https://doi.org/10.1007/s00253-015-6483-7  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00253-015-6483-7  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Proença  |D Daniela  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Leandro  |D Clara  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Garcia  |D Miguel  |u Technophage, SA, Av. Professor Egas Moniz, Ed. Egas Moniz, piso 2, 1649-028, Lisboa, Portugal  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Pimentel  |D Madalena  |u Centro de Patogénese Molecular, Unidade dos Retrovírus e Infecções Associadas (CPM-URIA), Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a São-José  |D Carlos  |u Centro de Patogénese Molecular, Unidade dos Retrovírus e Infecções Associadas (CPM-URIA), Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/12(2015-06-01), 5137-5149  |x 0175-7598  |q 99:12<5137  |1 2015  |2 99  |o 253